Cumberland Pharmaceuticals
CPIX
31 hedge funds and large institutions have $12.3M invested in Cumberland Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 8 closing their positions.
1,533% more call options, than puts
Call options by funds: $245K | Put options by funds: $15K
6.03% less ownership
Funds ownership: 30.64% → 24.61% (-6%)
6% less funds holding
Funds holding: 33 → 31 (-2)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
32% less capital invested
Capital invested by funds: $18.1M → $12.3M (-$5.82M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$230K |
| 2 |
HBCM
Heron Bay Capital Management
Bloomfield Hills,
Michigan
|
+$158K |
| 3 |
BlackRock
New York
|
+$87.7K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$48.7K |
| 5 |
Morgan Stanley
New York
|
+$46.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAM
Berkshire Asset Management
Wilkes Barre,
Pennsylvania
|
-$692K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$682K |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$635K |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$304K |
| 5 |
Walleye Capital
New York
|
-$298K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $7.04K | +$9.96K | +2,102 | New |
|
|
NA
27
NewEdge Advisors
New Orleans,
Louisiana
| $4.78K | +$6.76K | +1,428 | New |
|
|
CAL
28
Capital Advisors Ltd
Shaker Heights,
Ohio
| $1K | – | – | – |
|
29
Bank of America
Charlotte,
North Carolina
| $315 | +$123 | +26 | +38% |
|
30
Barclays
London,
United Kingdom
| $7 | +$9 | +2 | New |
|
|
HNB
31
Huntington National Bank
Columbus,
Ohio
| $3 | – | – | – |
|
|
BAM
32
Berkshire Asset Management
Wilkes Barre,
Pennsylvania
| – | -$692K | -153,810 | Closed |
|
|
33
Adage Capital Partners
Boston,
Massachusetts
| – | -$635K | -150,000 | Closed |
|
|
EI
34
EAM Investors
Solana Beach,
California
| – | -$304K | -71,776 | Closed |
|
|
35
Walleye Capital
New York
| – | -$298K | -70,419 | Closed |
|
|
SSA
36
Schonfeld Strategic Advisors
New York
| – | -$75.7K | -17,900 | Closed |
|
|
CC
37
Centiva Capital
New York
| – | -$6.77K | -1,600 | Closed |
|
38
Wells Fargo
San Francisco,
California
| – | -$1.06K | -250 | Closed |
|
39
JP Morgan Chase
New York
| – | -$80 | -19 | Closed |
|
CPIX Hedge Fund Activity: Q2 2025 in Review
31 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q2 2025, worth a combined $12.3M — down 32% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CPIX and 6 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was Citadel Advisors, adding an estimated $230K. The largest seller was Berkshire Asset Management, exiting entirely with an estimated $692K sold.
- 31 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q2 2025, down from 33 in Q1 2025.
- Funds reported $12.3M of Cumberland Pharmaceuticals stock for Q2 2025, down 32% quarter-over-quarter.
- 6 funds opened new Cumberland Pharmaceuticals positions in Q2 2025 and 8 closed out, a net change of -2 holders.
- The largest Cumberland Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $230K added.
- The largest Cumberland Pharmaceuticals seller in Q2 2025 was Berkshire Asset Management, an estimated $692K sold.
Based on aggregated 13F filings for Q2 2025.